MedTrace Logo

Dexmedetomidine Dose-Dependent on Lung Function and AQP1 in One-Lung Ventilation Surgery

NCT07145814 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-08-28

No results posted yet for this study

Summary

This randomized controlled trial evaluated the dose-dependent effects of dexmedetomidine (DEX) on pulmonary function and aquaporin-1 (AQP1) expression during one-lung ventilation (OLV) in thoracoscopic surgery.

Conditions

  • Acute Lung Injury(ALI)

Interventions

DRUG

dexmedetomidine 0.3 µg/kg/h

Following Anesthesia induction, dexmedetomidine (DEX) Low Dose group received a DEX loading dose (0.5 µg/kg over 10 min), followed by continuous infusions of 0.3 µg/kg/h, respectively, until 30 minutes before the end of the operation.

DRUG

dexmedetomidine 0.5 µg/kg/h

Following Anesthesia induction, dexmedetomidine (DEX) high dose group received a DEX loading dose (0.5 µg/kg over 10 min), followed by continuous infusions of 0.5 µg/kg/h, respectively, until 30 minutes before the end of the operation.

DRUG

0.9 % saline

Placebo group received an equivalent volume of 0.9% saline.

Sponsors & Collaborators

  • People's Hospital of Guangxi Zhuang Autonomous Region

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-05
Primary Completion
2019-03-29
Completion
2019-03-29

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07145814 on ClinicalTrials.gov